Numax data gives boost to MedImmune

Some of the analysts following MedImmune have been bullish about its prospects for Numax, a successor therapy to its blockbuster Synagis. The treatment for respiratory infections in infants produced preliminary data in Phase III that augurs well for its future revenue potential. MedImmune announced that Numax reduced respiratory infection in infants by 26 percent in comparison to Synagis. Some think Numax could earn more than the billion-plus dollars MedImmune makes from Synagis. By 2010 one analyst estimates that Numax will earn $890 million. Synagis, meanwhile, is expected to garner $1.13 billion in sales this year, sinking to $660 million in 2010.

- read this report from the Washington Business Journal

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.